NASDAQ$HSIC

Henry Schein Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Henry Schein reported a decrease in net sales but an increase in non-GAAP diluted EPS for Q3 2022.

Henry Schein reported a decrease in net sales by 3.5% compared to Q3 2021, but an increase in non-GAAP diluted EPS from $1.10 to $1.15. The company's internal sales increased by 6.8% in local currencies when excluding sales of PPE and COVID-19 test kits. The company narrows its 2022 non-GAAP diluted EPS guidance range, reflecting confidence in the business's strength.

  • Net sales decreased by 3.5% to $3.1 billion compared to Q3 2021.
  • GAAP diluted EPS was $1.09, compared to $1.15 in Q3 2021.
  • Non-GAAP diluted EPS increased to $1.15, compared to $1.10 in Q3 2021.
  • Full-year 2022 non-GAAP diluted EPS guidance is $4.79 to $4.87.

Headline financials

Total Revenue

$3.07B

Previous: $3.18B-3.5%
EPS (adj)

$1.15

Previous: $1.10+4.5%
Free Cash Flow

$150M

Previous: $162M-7.6%
Net Income

$150M

Previous: $162M-7.6%
Operating Income

$211M

Previous: $211M+0.1%
Gross Profit

$914M

Previous: $912M+0.2%
Cash & Equivalents

$123M

Previous: $119M+3.4%
Total Assets

$8.53B

Previous: $8.42B+1.3%
Stock-Based Comp

$17M

Previous: $27.5M-38.3%

Revenue & EPS history

Henry Schein · Revenue · Quarterly

$3.07B

Q3 2022-3.5%vs Q3 2021
Beat estimate in 8 of 15 quarters(53%)
ActualEstimate

Revenue by segment

Henry Schein · $2.9B total across 2 segments · Q3 2022

  • Global Dental
    $1.8B+0.0%
  • Global Medical
    $1.1B-8.3%

Forward guidance

Henry Schein provided guidance for 2022 non-GAAP diluted EPS to be $4.79 to $4.87. Full-year 2022 sales growth is expected to be approximately 1.5% to 2.5% over 2021.

Tailwinds

  • Full-year 2022 non-GAAP diluted EPS is expected to grow 6% to 8% compared to 2021.
  • Full-year 2022 non-GAAP diluted EPS is expected to grow 7.5% to 9.5% compared to 2021 GAAP diluted EPS.
  • Guidance assumes foreign currency exchange rates remain consistent with current levels.
  • Guidance assumes end markets will remain consistent with current market conditions.
  • Guidance assumes no material adverse market changes associated with COVID-19.

Headwinds

  • Full-year 2022 sales of COVID-19 test kits are expected to decrease 25% to 30% from 2021.
  • Full-year 2022 sales of PPE are expected to decrease 30% to 35% from 2021.
  • Combined sales of PPE and COVID-19 test kits are expected to be approximately 30% lower than in 2021.
  • Guidance excludes potential future acquisitions.
  • Guidance excludes integration and restructuring expenses.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-0.4%

Avg return

Earnings day

-0.5%

Avg return

5 days after

-0.6%

Avg return

30 days after

45%

31 / 69 earnings

Positive

+11.1%

Q4 2021

Best reaction

-8.5%

Q3 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.3%-1.6%+4.6%
Q4 2025+5.8%+2.3%-8.5%
Q3 2025+10.9%+11.2%+13.5%
Q1 2025+2.0%+5.1%+7.8%
Q4 2024-2.3%-7.0%-10.6%
Q3 2024-3.2%-6.0%+0.2%
Q2 2024-5.4%-0.9%+0.4%
Q1 2024+6.2%+7.0%+0.1%
Q4 2023-5.1%-4.6%-6.3%
Q3 2023+7.5%+7.3%+15.5%
Q2 2023-2.8%-1.8%-5.1%
Q1 2023-4.5%-4.2%-6.1%
Q4 2022-6.2%-7.5%-12.8%
Q3 2022+1.8%+6.2%+21.2%
Q2 2022-4.9%-3.8%-7.3%
Q1 2022+7.4%+6.6%+5.6%
Q4 2021+11.1%+10.1%+14.5%
Q3 2021+3.0%+4.5%-6.7%
Q2 2021-4.8%-5.2%-2.3%
Q1 2021+6.6%+8.9%+5.3%
Q4 2020-8.5%-6.5%-5.3%
Q3 2020-5.0%-3.0%+4.6%
Q2 2020-5.3%-4.4%-6.9%
Q1 2020+0.4%+2.9%+20.6%
Q4 2019-8.4%-14.4%-38.9%
Q3 2019+4.4%+4.8%+5.2%
Q2 2019-3.2%-2.3%-4.2%
Q1 2019+8.6%+8.9%+8.6%
Q4 2018-5.0%-5.2%-5.2%
Q3 2018+3.1%+0.8%+3.3%
Q2 2018-0.5%-3.6%+0.5%
Q1 2018-6.1%-4.4%-6.7%
Q4 2017-1.2%-2.1%-5.2%
Q3 2017-8.5%-13.6%-13.0%
Q2 2017-7.7%-7.2%-4.9%
Q1 2017+0.6%+0.3%+5.2%
Q4 2016+2.7%+3.2%+2.0%
Q3 2016+4.6%+6.2%+1.7%
Q2 2016-7.1%-8.4%-8.6%
Q1 2016-2.5%
Q4 2015+7.0%
Q3 2015+1.1%
Q2 2015-1.9%
Q1 2015-0.4%
Q4 2014+0.9%
Q3 2014+5.4%
Q2 2014-1.8%
Q1 2014-1.7%
Q4 2013+0.1%
Q3 2013-2.6%
Q2 2013-0.3%
Q1 2013+2.1%
Q4 2012-2.2%
Q3 2012-0.6%
Q2 2012+1.8%
Q1 2012+2.4%
Q4 2011+3.4%
Q3 2011-6.4%
Q2 2011-2.3%
Q1 2010-2.0%
Q1 2011+0.5%
Q4 2010-3.9%
Q1 2009-3.9%
Q4 2008-3.9%
Q3 2009-4.1%
Q3 2010-4.1%
Q2 2010+2.1%
Q4 2009+2.1%
Q2 2009+2.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro